Despite the advent of biologic agents, preventing bone damage in rheumatoid arthritis (RA) remains a challenging endeavor. Due to insufficient understanding of the mechanisms that trigger RA onset and determine disease severity, most current and emerging drugs are targeted at generic "downstream" immune pathways or inflammatory cytokines. As a result, drug failure and/or side effects are all too common.
The etiology and pathogenesis of RA are incompletely understood. However, it has long been observed that the majority of RA patients carry HLA-DRB1 alleles that code a 5-amino acid sequence motif called the "shared epitope" (SE) in region 70-74 of the DRb chain (1). The SE not only confers a higher risk of RA, but it also increases the likelihood of developing more severe disease. SE-coding HLA-DRB1 alleles are associated with earlier disease onset and accelerated bone damage (2) (3) (4) (5) . Furthermore, there is evidence of a gene-dose effect, where the extent of bone destruction in RA correlates positively with the number of SEcoding HLA-DRB1 alleles (3) (4) (5) .
The underlying mechanisms by which the SE affects susceptibility to, or the severity of, RA are unknown. We have recently identified the SE as a signal transduction ligand that binds to a well-defined site on cell surface calreticulin (6) in a strictly allele-specific manner and activates nitric oxide-mediated signaling (7) (8) (9) (10) (11) , with resultant enhanced osteoclast (OC) differentiation and activation both in vitro and in vivo (12, 13) .
OC-mediated bone damage is a common and unfortunate outcome in RA (14, 15) . In addition to juxtaarticular bone erosion, RA patients also experience periarticular and systemic osteoporosis (16) . The common mechanism underlying these pathologic changes of bone is believed to involve dysregulation of the balance between bone formation and resorption due to excessive cellular activity of OCs (17) as a result of intricate crosstalk with other cells in the synovium that produce RANKL (18) (19) (20) .
In previous studies, we demonstrated that the SE ligand has a dual enhancing effect on OC differentiation and activation in vitro: an indirect effect through polarization toward RANKL-expressing Th17 cells and a direct differentiation effect on OC precursors. When administered in vivo to mice with collagen-induced arthritis (CIA), the SE ligand was shown to increase joint swelling, abundance of active OCs in synovial tissue, and erosive bone damage (12, 13) .
Given the emerging evidence that the SE acts as a signal transduction ligand that directly contributes to bone damage in arthritis, we explored ways to specifically inhibit this pathway. Here we describe a peptidomimetic SE-antagonistic ligand (SEAL) with highly potent antiosteoclastogenic and antiarthritic effects. These findings suggest that targeting the SE-activated pathway might be a useful therapeutic strategy.
MATERIALS AND METHODS
Reagents, peptidomimetics, cells, and mice. FicollPaque, 4,5-diaminofluorescein diacetate (DAF-2-DA), macrophage colony-stimulating factor (M-CSF), RANKL, chicken type II collagen, and Freund's complete adjuvant (CFA) were purchased from sources described previously (13) . All other commercial reagents were purchased from Sigma. Linear 5-mer peptides DKCLA, QKCLA, and DERAA, as well as 15-mer peptides 65-79*0401 (KDLLEQKRAAVDTYC) and 65-79*0404 (KDLLEQRRAAVDTYC), were synthesized and purified (.90%) as described elsewhere (9, 10) . The urea backbone cyclic peptidomimetics, designated generically as HS(m-n)c Trp, were synthesized according to a previously described procedure (21, 22) using various alloc-protected glycine building units, where m represents the number of methylene groups in the N-alkyl chain on the glycine building unit at position 2, and n represents the number of methylene groups in the N-alkyl chain on the glycine building unit at position 6.
A tryptophan residue at position 1 was used for tracing and quantification.
The isolation of human peripheral blood mononuclear cells (PBMCs) and mouse primary bone marrow cells (BMCs) and the culture of M1 fibroblasts have previously been described (13) .
DBA/1 mice (6-10 weeks old) were purchased from The Jackson Laboratory. Mice were maintained and housed at the Unit for Laboratory Animal Medicine facility at the University of Michigan. All experiments were performed in accordance with protocols approved by the University Committee on Use and Care of Animals.
Surface plasmon resonance (SPR) analysis. A Biacore 2000 biosensor system was used to assay the interaction between soluble ligands and recombinant mouse calreticulin (6, 11) . SPR assay is based on a biosensor chip with a Dextrancoated gold surface that is coated with a covalently immobilized protein. Binding interactions between an injected ligand (the "analyte") and the immobilized protein result in SPR signals that are directly proportional to the amount and molecular mass of the ligand. Results are read in real time as resonance units (RU).
Before use, biosensor chips CM5 (Biacore) were preconditioned in water at 100 ml/minute by applying 2 consecutive 20-ml pulses of 50 mM NaOH, followed by 10 mM HCl, and finally 0.1% sodium dodecyl sulfate. The CM5 surface was activated by a 7-minute injection of 200 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride in 50 mM N-hydroxysuccinimide. Purified calreticulin was immobilized by standard primary amine coupling at 258C in HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 0.005% surfactant P20), at a flow rate of 10 ml/minute. The protein was injected manually at a concentration of 100 mg/ml until approaching 5,500 RU. The remaining activated groups were blocked by ethanolamine (1M).
Binding assays were performed at 258C in a binding buffer (10 mM HEPES, pH 7.4, 50 mM KCl, 0.5 mM CaCl 2 , 100 mM ZnCl 2 , and 0.005% surfactant P20) at a flow rate of 10 ml/minute. Ligands were applied to the analyte at various concentrations. The RU signal intensity at a given molar concentration is proportional to the molecular mass of the analyte. Accordingly, when a competitive small ligand is mixed with a larger ligand, a drop in the signal relative to the RU produced by the latter ligand alone is observed. This characteristic was used in our study to determine the competitive inhibition of the binding of the 15-mer peptides 65-79*0401 (MW 1,751 daltons) or 15-mer peptide 65-79*0404 (MW 1,751 daltons) to calreticulin by the 5-mer linear peptide DKCLA (MW 590 daltons) or the cyclic DKCLA (cDKCLA) mimetic (MW 902 daltons). All SPR data were calculated using the BIAevaluation version 3.0.1 program (Biacore).
In vitro assays. Nitric oxide signal transduction assays were performed using the nitric oxide probe DAF-2-DA. The fluorescence level was recorded every 5 minutes over a period of 500 minutes using a Fusion aHT system (PerkinElmer Life Sciences) at an excitation wavelength of 488 nm and emission wavelength of 515 nm. In vitro assays for OC differentiation were performed using primary mouse BMCs isolated from femurs and tibias or using human PBMCs isolated from healthy blood donors. Mouse BMCs were cultured in 48-well plates (2 3 10 5 /well) a-minimum in essential medium supplemented with 10% fetal bovine serum, 100 units/ml of penicillin, 2062 LING ET AL and 100 mg/ml of streptomycin in the presence of 10 ng/ml of M-CSF alone during the first 2 days, followed by 4 additional days in the presence of 10 ng/ml of M-CSF plus 20 ng/ml of RANKL. Human OCs were differentiated from PBMCs derived from random blood donors, irrespective of their HLA-DRB1 genotype. Cells (2 3 10 5 /well) were cultured in 48-well plates for 7 days in 100 ng/ml of M-CSF and 100 ng/ml of RANKL supplemented with 10% fetal calf serum-Dulbecco's modified Eagle's medium. To quantify the number of OCs, cultures were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity using an acid phosphatase kit (Kamiya Biomedical) according to the manufacturer's instructions. TRAP-positive multinucleated OCs (.3 nuclei) were counted using a tissueculture inverted microscope.
CIA induction, in vivo compound administration, joint tissue studies, and imaging. DBA/1 mice were immunized with chicken type II collagen in CFA. Briefly, 50 ml of an emulsion containing 100 mg of chicken type II collagen in 25 ml of 0.05M acetic acid and 25 ml of CFA was injected intradermally at the base of the tail. Mice were injected intraperitoneally once a week for 7 weeks with 50 ml of either phosphate buffered saline (PBS), HS(4-4)c Trp, or HS(3-4)c Trp in PBS. Arthritis severity was determined using a 4-point visual scoring system for each paw, where 0 5 no arthritis, 1 5 swelling and redness confined to the digits, 2 5 minor swelling and redness spreading from the digits to the distal paw, and 3 5 major swelling and redness extending proximally from the paw.
Limbs were dissected and decalcified in 10% EDTA. After decalcification, the specimens were processed for paraffin embedding and serial sectioning. The histology sections were deparaffinized, rehydrated, and stained for TRAP activity using a commercial kit. To determine OC abundance, TRAP-positive multinucleated cells were counted. Data are reported as the mean 6 SEM of the total number of OCs in the front and hind paws plus both knees.
For micro-computed tomography (micro-CT), the front and hind limbs were dissected, fixed in 10% formalin, and stored in 70% ethanol. Limbs were scanned ex vivo with a micro-CT system (eXplore Locus SP; GE Healthcare Canada) in distilled water. The protocol included a source powered at 80 kV and 80 mA. In addition to a 0.508-mm aluminum filter, an acrylic beam flattener was used to reduce beam-hardening artifact. Exposure time was defined as 1,600 msec/frame, with 400 views taken at increments of 0.58. With 4 frames averaged and binning at 2 3 2, the images were reconstructed with an 18-mm isotropic voxel size.
Radiographs were obtained using a microradiography system (Faxitron) with the following operating settings: peak voltage of 27V, anode current of 2.5 mA, and an exposure time of 4.5 seconds. Coded radiographs were evaluated by an experienced rheumatologist (JH) who was blinded with regard to the treatment group. Bone erosions were scored on a scale of 0-5 for each of the 4 paws.
Docking models. BioMed CAChe 6.1 software (Fujitsu) was used for modeling of the interaction between ligands and the calreticulin P-domain. Cyclic peptidomimetics, which were loaded as flexible molecules, or the physiologically folded SE (residues 70-74 in the b-chain third allelic hypervariable region of HLA-DR4; PDB ID 2SEB) as a rigid conformation, were used as ligands. Rat calreticulin P-domain (PDB ID 1HHN) in its rigid conformation was used as receptor. Docking scores were calculated using BioMed CAChe 6.1 software. In all cases, the minimum potential energy and chemical bonds were determined for the most stable geometry.
Statistical analysis. Data are expressed as the mean 6 SEM. Except where indicated otherwise, statistical analyses were performed using Student's t-test. P values less than 0.05 were considered significant.
RESULTS
DKCLA, a short linear synthetic peptide with SEAL properties. We identified a 5-mer peptide expressing the sequence DKCLA that interacted with calreticulin in an SPR-based assay ( Figure 1A) , and specifically inhibited the interaction between calreticulin and 15-mer peptide SE ligands corresponding to the 65-79 region coded by HLA-DRB1*04:01 ( Figure 1B) or by DRB1*04:04 ( Figure 1C ) at a 50% inhibition concentration (IC 50 ) of 67 mM ( Figure 1D ) and 289 mM (Figure 1E ), respectively. Additionally, linear DKCLA specifically blocked SE ligand-activated nitric oxide signaling ( Figure 1F) . Thus, the linear peptide DKCLA is a low-potency competitive inhibitor of the SE ligand, a functional characteristic referred to as SE-antagonistic ligand.
DKCLA peptidomimetics. Linear peptides are short-lived, and their biologic activity is further compromised by their random conformation in solution. Accordingly, as a peptide-stabilization strategy, we used a previously described procedure (21, 22) to synthesize a library of backbone cDKCLA analogs, all carrying an identical primary sequence, but differing in the size of their ring ( Figure 1G) . Members of this library were screened in SE ligand-activated nitric oxide signaling assays to determine the relative SEAL potency of individual compounds in vitro. Of the 16 analogs tested, several were found to be exceptionally potent (e.g., the compounds HS c Trp, HS c Trp, and HS Figure 1H ). The lead compound HS(4-4)c Trp was tested in SPR assays, and was found to be a potent M ( Figure 1I ). Thus, cDKCLA compound HS(4-4)c Trp is a 1,000,000 times more potent SEAL than the linear DKCLA peptide.
In vitro inhibition of OC differentiation by cDKCLA compounds. Since OCs play a key role in bone erosion-associated conditions, an attempt to inhibit these cells is a desirable therapeutic goal. Given the high SEAL potency of compounds HS(4-4)c Trp and HS(3-3)c Trp in signal transduction (Table 1) , we carried out experiments to determine their effectiveness as OC inhibitors.
We found that in mouse cells ( Figure 1J ), the lead cDKCLA compound HS(4-4)c Trp very efficiently inhibited RANKL-activated OC differentiation. Moreover, it significantly inhibited the incremental SE-activated OC differentiation. SEAL activity was found to be structurespecific, since the cDKCLA analog HS(3-4)c Trp, which carries an identical core amino acid sequence and only differs in the ring size, failed to inhibit OC differentiation ( Figure 1K ), consistent with its low inhibitory effect in signal transduction studies ( Table 1 ). The antiosteoclastogenic effects of SEAL compounds HS(4-4)c and HS(3-3)c were tested in human PBMCs as well, and showed potent antiosteoclastogenic effects in the absence or presence of an exogenously added SE ligand ( Figures 1J and L) . The effect was found in both SE-positive and SE-negative PBMCs (results not shown). Additionally, preliminary data suggest that similar to their effect on PBMC-derived OCs, SEAL compounds inhibited signal transduction in human fibroblast-like synoviocytes irrespective of the SE status of the donor as well (results not shown).
Cyclic DKCLA analog-specific effects in vivo. The effects of SEAL compounds were studied in mice with CIA. As shown in Figure 2 , mice injected intraperitoneally once a week with picogram doses of HS(4-4)c Trp experienced delayed onset (Figure 2A ), lower incidence ( Figure 2B ), and significantly milder ( Figure 2C ) arthritis. Histologically, their joints showed less-abundant OCs in the synovial tissues ( Figures 2D and E) . Interestingly, although at the end of the treatment period (day 45 postimmunization) joint swelling was seen in all groups, pannus from PBS-treated mice showed greater lymphocytic infiltration than did the synovial tissue from HS(4-4)c Trp-treated mice ( Figure 2E ). Micro-CT and radiographic imaging demonstrated a lesser extent of bone destruction in the treated groups ( Figures 2F and  G) . In contrast and consistent with its inactivity in vitro, the HS(3-4)c Trp analog had no effect on the day of arthritis onset ( Figure 3A) , the incidence of arthritis (Figure 3B ), the disease severity ( Figure 3C ), the radiographic bone damage (Figure 3D ), or the abundance of OCs in synovial tissues ( Figure 3E) .
No behavioral, physical, radiologic, or histologic aberrations were noticed in SEAL-treated mice as compared to controls. Untreated and treated mice (highest dosage 360 pg/gm of body weight weekly for up to 7 weeks) showed similar general health parameters (body weight, fur appearance, mobility, and food and water consumption rates).
As mentioned above, the compounds HS(4-4)c Trp and HS(3-4)c Trp share an identical core sequence, but differ slightly in their ring size. This minor structural 2066 LING ET AL dissimilarity nevertheless accounted for a major functional disparity between the 2 compounds. To gain better insights into the structure-function correlates of the 2 compounds, we docked them virtually onto a physiologically folded calreticulin P-domain (6), using BioMed . Thus, the inactive analog HS(3-4)c Trp, similar to the naturally folded SE ligand, was predicted to generate a "bridging" effect across the SE binding pocket, while the SEAL compound HS(4-4)c Trp displayed a strong focal interaction with calreticulin residue Glu 257 at the center of that pocket (Figure 4) . Taken together, the data in Figure 4 and Table 2 indicate that despite their nearly identical chemical structure, the 2 functionally disparate compounds displayed distinct molecular interactions with the SE binding site on calreticulin.
DISCUSSION
The main significance of the findings reported herein is the identification of the SE/calreticulin pathway as a novel therapeutic target. To date, treatment modalities in RA have targeted cytokines, their receptors, or other players in the immune-activated final common pathway. Due to their involvement in "downstream" segments of RA pathogenesis, these targets are often redundant and/or nonspecific. As a result, current treatment modalities are often ineffective, and/or they carry high rates of side effects, mainly infection (23) . The advantage of a SEAL-based therapeutic approach over current or emerging drugs is that it addresses an unmet need by offering a potent intervention strategy that specifically targets an "upstream" segment of the pathogenic cascade. The compounds described herein were found to be highly potent, both in vitro and in vivo. For example, compounds HS(4-4)c Trp and HS(3-3)c Trp competitively blocked SE signaling effects and inhibited OC differentiation at low picomolar concentrations, a 1,000-fold higher potency than JAK inhibitors (24) . The in vivo effect of compound HS(4-4)c Trp, likewise, was much more potent than that of emerging drugs reported to exert therapeutic efficacy in CIA at doses in the milligram-per-kilogram range (24) (25) (26) . In contrast, compound HS(4-4)c Trp described herein achieved diseaseamelioration effects at doses in the nanogram-perkilogram range, a 1,000,000-fold higher potency.
Interestingly, despite its seemingly modest antiosteoclastogenic effect in vitro ( Figures 1J and L) , SEAL compound HS(4-4)c Trp was highly effective in diminishing tissue OCs when administered in vivo to mice with CIA ( Figure 2D ). The likely explanation for the apparent discrepancy is that in vitro assays do not accurately replicate the cellular events that take place in vivo. Specifically in this case, in vitro OC-differentiation assays were carried out using mouse BMCs ( Figure 1J ) or human PBMCs ( Figure 1L ), while in vivo, the abundance of OCs was determined within mouse synovial tissue, which represents a different cellular milieu. Second, in vitro OC-differentiation protocols used selected pro-osteoclastogenic factors (M-CSF and RANKL), whereas the in vivo process involved additional proosteoclastogenic and antiosteoclastogenic factors. Third, the in situ concentrations of RANKL and M-CSF are likely to be lower than those used to artificially stimulate robust OC differentiation in vitro.
SEAL compound-treated CIA mice showed delayed arthritis onset and decreased incidence; however, both the treated and control groups eventually developed joint swelling and reached equivalent disease incidence. This observation is consistent with our previous studies demonstrating that the arthritogenic effect of SE agonist ligands affect joint swelling in the early phase of CIA, but less so in the chronic phase (12, 13) . The mechanistic basis of the differential effect on early versus late joint swelling is unknown, but is likely to be related to the fact that the early and late stages of CIA are distinct in their pathogenic mechanisms and in the degree of their responsiveness to therapeutic interventions (27) (28) (29) (30) (31) . Similarly consistent with our previous findings with SE agonist ligands (12, 13) , which demonstrated a disproportionate impact on bone erosions relative to their effects on joint swelling, the SEAL compound reversed this trend by affecting primarily bone damage. Such a differential effect is not without precedent, as disparate severities of joint inflammation versus bone erosion have previously been reported in experimental arthritis models (32, 33) as well as in RA in humans (34) . Better understanding of the mechanisms governing bone selectivity by SEAL compounds could provide important new insights into the pathogenic mechanisms that specifically underlie inflammation versus bone damage.
It should be pointed out that SEAL compounds inhibited basal osteoclastogenesis in vitro even in the absence of the SE ligand and ameliorated CIA in mice that do not carry SE-coding MHC class II alleles. Therefore, consistent with the SE ligand theory (for a discussion, see refs. 35 and 36) , it is reasonable to propose the existence of a physiologic calreticulin-binding ligand capable of OC activation during healthy bone remodeling. There are several physiologic ligands that the SE ligand could potentially mimic. For example, circulating levels of adiponectin, a known calreticulin ligand (37) , have been shown to correlate with the extent of radiographic bone damage in RA (38) . It is noteworthy that adiponectin facilitates Th17 polarization (39) and can activate OCs (for review, see ref. 40 ). Thrombospondin 1, likewise a well-characterized calreticulin ligand (41) that is implicated in RA pathogenesis (42, 43) , facilitates Th17 polarization (44) and activates OCs (45) .
Obviously, identification of the specific physiologic calreticulin ligand that the SE may be mimicking requires further study. However, irrespective of the identity of that physiologic ligand, the model proposed here hypothesizes that the SE may facilitate OC activation and bone damage by mimicking a putative physiologic ligand. Accordingly, SEAL compounds may ameliorate OC activation and arthritis through competitive inhibition of a physiologic ligand, independently of the presence or absence of an SE ligand. This model further posits that individuals with SE-coding HLA-DRB1 alleles are at higher risk of developing erosive arthritis due to the high abundance of cell surface SE-expressing HLA-DR molecules that mimic the physiologic OC-activating ligand. Under certain genetic and environmental circumstances, the SE ligand may overactivate the innate pathway, with resultant excessive activation of OCs. In this context, it is worth noting that SE-associated bone damage is not unique to RA, as SE-coding HLA-DRB1 alleles have been shown to associate with accelerated bone erosion in patients with psoriatic arthritis (46) , patients with periodontal disease (47) , and patients with SLE (48) .
Beyond offering new insights into the pathogenesis of bone damage in arthritis, our findings illustrate the therapeutic targetability of the SE/calreticulin pathway by highly specific, rationally designed SEAL compounds. The compounds presented here were highly potent, both in vitro and in vivo, and showed exquisite structure-activity relationships. These facts could facilitate future compound optimization efforts. From a medicinal chemistry perspective, it is also worth noting that the cysteine residue does not appear to play a role in the antagonist's interaction model with calreticulin ( Figure 4 and Table 2 ). Additionally, since the inactive compound HS(3-4)c Trp contains cysteine in the same position as the active compounds HS(4-4)c Trp and HS(3-3)c Trp, the cysteine residue, including its thiol side chain, is unlikely to play a functional role in the biologic effects of these compounds.
The new strategy presented herein may be safer than using prevailing drugs because of the unique role played by this pathway at an "upstream" phase in RA pathogenesis. The SE is the single most significant risk factor for RA. It determines susceptibility, severity, and disease penetrance (49) . Thus, different from effector cytokines or intracellular enzymes, this pathway is involved in the early segments of disease etiology and pathogenesis. Targeting such an "upstream" pathway might be more effective and would likely produce fewer side effects.
In conclusion, the findings of this study suggest that SEAL compounds could be useful tools for examining the mechanisms governing bone erosion in various conditions, including RA. Furthermore, the results provide a rationale and early medicinal information that could help in the development of specific, potent, safe, and inexpensive drugs for arthritis and other erosive bone conditions.
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